Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.78, $0.06 better than the analyst estimate of $0.72. Revenue for the quarter came in at $107.95 million versus the consensus estimate of $109.32 million.

Emergent Biosolutions (reaffirms), seeing FY2012 revenue of $280-$300 million, versus the consensus of $304.5 million.

For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.

Earnings Guidance